Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2300-0.0500 (-3.91%)
At close: 04:00PM EST
1.2200 -0.01 (-0.81%)
After hours: 04:32PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2800
Open1.3100
Bid1.2800 x 2200
Ask1.3000 x 1800
Day's Range1.2300 - 1.3700
52 Week Range1.1800 - 11.5800
Volume1,853,920
Avg. Volume1,590,633
Market Cap135.664M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.7940
Earnings DateNov 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.58
  • GlobeNewswire

    Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates

    - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced muscle tropism and microdystrophin expression - - Company enters 2022 with approximately $210 million in cash and investments - - Ian F. Smith, Chair of the Board of Directors, to assume role of Executive Chair - CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a

  • GlobeNewswire

    Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET. Following the prepared remarks, Mr. Ganot will be available for Q&A. Institutional investors interested

  • Zacks

    All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy

    Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advertisement
Advertisement